Postoperative pain following laser fistula closure versus ligation of the intersphincteric fistula tract: A prospective double‐blinded randomized controlled trial
World Journal of Surgery · 2024
DOI: 10.1002/wjs.12242 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift World Journal of Surgery, 2024. Verfasst von Jolynn Qian Lin Low und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia. Hauptthemen laut MEDLINE: Postoperative Pain, Rectal Fistula, Laser Therapy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Themen: Schmerzmanagement
Abstract (Originalsprache)
Background
Prior studies focus primarily on surgical outcomes of anal fistula treatment, such as healing rates, rather than patient‐reported outcomes, such as postoperative pain, which could influence surgical choice.
Objective
To compare pain scores at 6 and 24 h postoperatively between laser closure and ligation of the intersphincteric tract for anal fistula.
Design
Prospective, double‐blinded randomized controlled trial. Settings A quaternary hospital in Malaysia. Patients Patients aged 18–75 years with high transsphincteric fistulas.
Intervention
Fistula laser closure versus ligation of the fistula tract (LIFT) treatment. Main Outcome Measures Pain scores, continence, quality of life (QOL), operative time, and treatment failure were compared using chi‐square, Fisher's exact test, student t ‐test, or Mann–Whitney with p < 0.05 denoting statistical significance.
Results
Fifty‐six patients were recruited (laser, n = 28, LIFT, n = 28). Median pain scores for laser versus LIFT at 6 h postoperatively were 1.0 versus 2.0 (Rest, p = 0.213) and 3.0 versus 4.0 (Movement, p = 0.448), respectively. At 24 h, this reduced to 2.5 in both arms at rest ( p = 0.842) but increased to 4.8 versus 3.5 on movement ( p = 0.383). Median operative time for laser was significantly shorter (32.5 min) than LIFT ( p < 0.001). Laser treated patients trended toward quicker return to work (10.5 vs. 14.0, p = 0.181) but treatment failure was similar (54% vs. 50%, p = 0.71). No patients developed postoperative incontinence. Mean SF‐36 scores increased from baseline (67.1 ± 17.0; 95% CI 63.6–82.4 vs. 71.3 ± 11.4; 95% CI 64.0–75.0) to 6 months postoperatively (77.7 ± 21.0; 95% CI 57.0–80.3 vs. 74.0 ± 14.3; 95% CI 67.6–81.4) regardless of the type of surgery ( P > 0.05).
Limitations
Patients with prior fistula surgery (approximately 20%) led to heterogeneity. The total laser energy delivered varied depending on fistula anatomy.
Conclusion
Laser fistula closure is an alternative to LIFT, with similar postoperative pain and shorter operative time despite more complex fistula anatomy in the laser arm, with a greater improvement in QOL. Trial Registration ClinicalTrials.gov: NCT06212739.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
ORCID-Profile: Retnagowri Rajandram, April Camilla Roslani
Zitieren
APA
Low, J. Q. L., Rajandram, R., Aziz, M. R. A., & Roslani, A. C. (2024). Postoperative pain following laser fistula closure versus ligation of the intersphincteric fistula tract: A prospective double‐blinded randomized controlled trial. World Journal of Surgery. https://doi.org/10.1002/wjs.12242
Vancouver
Low JQL, Rajandram R, Aziz MRA, Roslani AC. Postoperative pain following laser fistula closure versus ligation of the intersphincteric fistula tract: A prospective double‐blinded randomized controlled trial. World Journal of Surgery. 2024. doi:10.1002/wjs.12242
BibTeX
@article{Low2024,
author = {Low, Jolynn Qian Lin and Rajandram, Retnagowri and Aziz, Mohamed Rezal Abdul and Roslani, April Camilla},
title = {Postoperative pain following laser fistula closure versus ligation of the intersphincteric fistula tract: A prospective double‐blinded randomized controlled trial},
journal = {World Journal of Surgery},
year = {2024},
doi = {10.1002/wjs.12242}
}
EUVIMED